天天舔天天爽_视频日韩_成人网线_天天草草草_免费一级在线观看_色综合色综合色综合色综合

Syndax  
Syndax制藥專注于運用表觀遺傳學(xué)相關(guān)的方法，克服在實體瘤治療中發(fā)生的耐藥性問題。公司擁有Entinostat在全球的專利權(quán)。Entinostat是一種口服的、高選擇性的組蛋白去乙?；福℉DAC）抑制劑，用于晚期乳腺癌和肺癌的臨床治療。同樣在一組非小細(xì)胞肺癌患者的治療中（ENCORE401），Entinostat與EGFR-TKI厄洛替尼配合使用也取得了積極有效的結(jié)果。美國國家癌癥研究所（NCI）和Syndax制藥就Entinostat的發(fā)展達(dá)成了合作研究和開發(fā)協(xié)議，旨在改善晚期癌癥和難治性癌癥的存活率。

Syndax is focused on employing epigenetic strategies to overcome the problem of resistance in oncology care in solid tumors. The company holds worldwide rights to entinostat, an oral, highly selective histone deacetylase (HDAC) inhibitor in late-stage clinical development for the treatment of advanced breast cancer and lung cancer. A randomized, placebo-controlled Phase 2 study of entinostat in combination with aromatase inhibitors in breast cancer (ENCORE 301) demonstrated an improvement in both progression-free survival and overall survival, providing the basis for the evaluation of entinostat in pivotal Phase 3 testing in metastatic breast cancer. Entinostat also demonstrated promising results in a subset of non-small cell lung cancer patients when given in combination with the EGFR-TKI erlotinib (ENCORE 401). NCI and Syndax are collaborating on the development of entinostat under a Cooperative Research and Development Agreement aimed at improving survival in advanced, hard-to-treat cancers.

Read more: Syndax's Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer - FierceBiotech http://www.fiercebiotech.com/press-releases/syndaxs-entinostat-receives-breakthrough-therapy-designation-fda-treatment#ixzz2ejNENL8W
Subscribe at FierceBiotech